The bluebird bio lawsuits fall into four groups: two securities fraud class actions brought by investors, two rounds of shareholder derivative claims against officers and directors, a Delaware challenge to director pay, and a multi-year patent fight with San Rocco Therapeutics over the technology behind its gene therapies. Bluebird won or settled almost every one of them, and then sold itself to private equity firms Carlyle and SK Capital in June 2025 for less than $30 million.
The 2024 Securities Class Action Over Lyfgenia
The most prominent case against the company was filed in March 2024 by investor Garry Gill in the U.S. District Court for the District of Massachusetts, captioned Gill v. bluebird bio, Inc., Case No. 24-cv-10803.{1BusinessWire. Robbins Geller Rudman Dowd Announces Bluebird Bio Investors Have Opportunity to Lead Class Action} It alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 during a class period from April 24, 2023, through December 8, 2023.{2Federman & Sherwood. Federman Sherwood Announces Filing of Securities Class Action Lawsuit Against Bluebird Bio}
The complaint focused on two disclosures. Investors alleged that bluebird’s executives had created the misleading impression that its sickle cell gene therapy Lyfgenia could win FDA approval without a black box warning for blood cancers, and that the company had overstated the likelihood of receiving a Priority Review Voucher worth $103 million under a pre-negotiated sale agreement.{1BusinessWire. Robbins Geller Rudman Dowd Announces Bluebird Bio Investors Have Opportunity to Lead Class Action} When Lyfgenia was approved on December 8, 2023, it carried the black box warning, the FDA denied the voucher, and a competing Vertex Pharmaceuticals therapy was approved the same day without either drawback. Bluebird’s stock fell roughly 40%, from $4.81 to $2.86 per share.{3Zacks Levi Korsinsky. Bluebird Bio Inc. Class Action Lawsuit}
On May 23, 2025, Judge Patti B. Saris granted bluebird’s motion to dismiss the amended complaint. On the label claims, the court found that CEO Andrew Obenshain’s public statements about label discussions with the FDA were opinion, qualified with phrases like “I think” and “I don’t think,” and that Obenshain had already disclosed on a third-quarter 2023 earnings call that leukemia deaths would “certainly” appear on the label. On the voucher claims, the court held that the plaintiff had not pled the “strong inference of scienter” required by the securities laws, noting that bluebird had lined up a $103 million buyer for the voucher, suggesting genuine belief that it would be granted. Judge Saris characterized the theory as “fraud by hindsight.”{4FindLaw. Gill v. Bluebird Bio Inc.} Dismissal was with leave to amend within 30 days. The plaintiff did not amend, and the Clerk formally dismissed the case on July 1, 2025.{5Stanford Securities Class Action Clearinghouse. Bluebird Bio Inc. Securities Litigation}
The 2021 Securities Class Action Over LentiGlobin
Investors had sued bluebird once before on similar theories. A February 2021 class action in the same Massachusetts federal court alleged that the company had misled shareholders about the timeline for submitting a Biologics License Application for LentiGlobin, its beta-thalassemia gene therapy, over a class period from May 11, 2020, to November 4, 2020.{6PR Newswire. Berger Montague Investigates Alleged Securities Fraud Claims Against Bluebird Bio}
In November 2020, bluebird had pushed the BLA submission from 2021 to late 2022, citing FDA feedback on manufacturing comparability data and pandemic-related delays. The stock dropped nearly 17%. Investors alleged that bluebird had known its data was insufficient and had used the intervening months to raise $541.5 million in a stock offering.{6PR Newswire. Berger Montague Investigates Alleged Securities Fraud Claims Against Bluebird Bio}
The court dismissed the case with prejudice on April 21, 2022, finding that the complaint failed to plead scienter, loss causation, or material misstatements. The judge identified a “compelling” nonculpable inference that bluebird had designed its comparability study in good faith on the basis of available FDA guidance, and held that many of the challenged statements were forward-looking and protected by the Private Securities Litigation Reform Act’s safe harbor.{7Bloomberg Law. Bluebird Bio Officers Face New Derivative Suit Over Drug Claims}
Shareholder Derivative Suits
Two waves of derivative claims tracked the two securities cases. In 2021, shareholders sued bluebird’s directors and officers on the company’s behalf over the LentiGlobin disclosures. Judge Denise J. Casper consolidated two of those actions on July 1, 2021, as In re Bluebird Bio Inc. Stockholder Derivative Litigation, No. 1:21-cv-10614, and appointed co-lead counsel.{8Bloomberg Tax. Bluebird Bio Shareholders Get Lead Counsel for Derivative Suits}
A second derivative suit followed the Lyfgenia approval. Filed June 27, 2024, in the District of Massachusetts as No. 1:24-cv-11674, it alleged breach of fiduciary duty, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control tied to the sickle cell therapy rollout.{7Bloomberg Law. Bluebird Bio Officers Face New Derivative Suit Over Drug Claims}
The Delaware Director Pay Suit
In March 2020, a shareholder filed a derivative action in the Delaware Court of Chancery alleging that bluebird’s eight directors, including Chairman Daniel Lynch, were grossly overcompensated. The complaint cited 2018 average board pay of roughly $748,652 per director, about three times the average at companies of comparable size, and asked for disgorgement plus governance reforms.{9Law360. Bluebird Bio Directors Grossly Overpaid, Chancery Suit Says}
The case settled. Bluebird pledged to keep average board pay at or below the top quartile for non-employee directors at comparable companies through 2023, and agreed to pay up to $500,000 in attorneys’ fees to the shareholder’s counsel.{10Bloomberg Law. Bluebird Bio Ends Director Pay Challenge With Governance Pledge}
The San Rocco Patent Fight
The company’s longest-running dispute involved San Rocco Therapeutics, formerly Errant Gene Therapeutics, and U.S. Patent Nos. 7,541,179 and 8,058,061, covering a vector encoding a human globin gene. Errant Gene had held commercial rights under a 2005 exclusive license from Memorial Sloan Kettering Cancer Center that was terminated in 2011. Starting in 2017, Errant Gene sued Sloan-Kettering in New York state court for fraud, breach of contract, and unauthorized disclosure of confidential information to bluebird, and named bluebird itself in an unfair competition claim.{11NY Courts. Errant Gene Therapeutics v. Sloan-Kettering Institute for Cancer Research}
The parties signed a confidential settlement in November 2020. It did not last. In 2021, San Rocco sued bluebird and Third Rock Ventures in the U.S. District Court for the District of Delaware, alleging that Zynteglo and Lyfgenia infringed the same two patents. Bluebird argued that the 2020 settlement released the claims and that San Rocco lacked standing.{12Jus Mundi. San Rocco Therapeutics v. Bluebird Bio Memorandum}
Judge Richard G. Andrews sent both threshold questions to arbitration. In a February 2023 final award, arbitrator David W. Ichel ruled for San Rocco on each: the company held an exclusive, royalty-free commercial license with standing to sue, and the 2020 releases did not bar the patent claims.{13Jus Mundi. San Rocco Therapeutics v. Bluebird Bio Final Award}
Bluebird still won on the merits. On May 16, 2025, Judge Andrews granted summary judgment of noninfringement. The ruling turned on prosecution history estoppel: San Rocco had narrowed its patent claims during examination to define a “precise DNA sequence,” bluebird’s therapies did not use that sequence, and San Rocco could not recapture the ceded territory through the doctrine of equivalents.{14Bloomberg Law. Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies}
A related patentability appeal at the Federal Circuit, Case No. 24-2010, was voluntarily dismissed in August 2025, with each side bearing its own costs and no damages, royalties, or injunctive relief entered. Any underlying settlement terms were not disclosed.{15PatSnap. Bluebird Bio vs Sloan-Kettering Gene Therapy Patent Dispute Ends in Voluntary Dismissal}
Financial Collapse and Sale to Carlyle and SK Capital
The litigation played out against deepening financial distress. Bluebird’s own filings acknowledged “substantial doubt” about its ability to continue as a going concern.{16BioSpace. Bluebird Bio Reports Third Quarter 2024 Results} In February 2025, the company announced a sale to Carlyle and SK Capital for roughly $3 per share in cash plus a contingent value right of up to $6.84 per share if the therapy portfolio reached $600 million in annual net sales by the end of 2027. The board called it the “only viable solution” to avoid bankruptcy and warned that shareholders would likely receive nothing in a liquidation.{17STAT News. Bluebird Bio Sells Itself to Carlyle, SK Capital for Less Than $30 Million}
To secure enough shareholder participation, the buyers added a $5.00 per share cash option with no contingent value right.{18Bitget. What Happened to Bluebird Bio Stock} The deal closed on June 2, 2025, and bluebird bio stopped trading on the NASDAQ.{19BioSpace. Carlyle and SK Capital Receive All Required Regulatory Approvals} A company once valued above $10 billion sold for less than $30 million.{20Nature. Gene Therapy Commercialization Challenges}